+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 45 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of Efimosfermin Alfa in adults with known or suspected metabolic dysfunction-associated steatohepatitis MASH at fibrosis stages F2 or F3. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how this drug affects participants with this liver condition. Participants will be randomly assigned to one of three groups receiving Efimosfermin Alfa at dose level 1, Efimosfermin Alfa at dose level 2, or a placebo. The treatment is administered as an injection, and the study will track effects and adverse events over 52 weeks. The study includes multiple assessments, including liver fibrosis measurements and blood tests to monitor liver health and other related factors. During the study, participants will undergo regular evaluations including blood tests, imaging scans, and clinical assessments up to Week 52 to monitor safety, liver function, and fibrosis changes. Researchers will measure treatment-emergent adverse events, laboratory abnormalities, and changes in liver fibrosis and fat content using various biomarkers and imaging techniques. This detailed monitoring helps assess the treatments impact and safety profile throughout the study period.

Age: 18Years - 75YearsAll GendersPhase 3
66 locations
E

Actively Recruiting

Researchers are evaluating the effect of pegloticase given by two different methods along with methotrexate in adults with uncontrolled gout. This phase 3 trial compares subcutaneous under the skin injections of pegloticase at 18 mg every two weeks with intravenous into a vein injections of pegloticase at 8 mg every two weeks, both combined with weekly methotrexate. The main goal is to see which approach better maintains low serum uric acid levels during the sixth month. Participants will be randomly assigned to receive either pegloticase by subcutaneous injection or by intravenous infusion, both administered every two weeks, alongside oral methotrexate taken weekly. The trial is double-blind, meaning neither participants nor researchers know which form of pegloticase is given. Methotrexate is given orally concurrently. Treatment continues through at least six months with ongoing evaluations. During the study, participants will have regular assessments to monitor their response to treatment, including blood tests to measure serum uric acid levels and pegloticase concentrations. Safety will be closely observed, including monitoring for injection site reactions, infusion reactions, and anaphylaxis up to 48 weeks. The primary outcome measures participants who maintain normalized uric acid levels during Month 6, with follow-up lasting up to 48 weeks. Total participation may extend to the study completion in June 2028.

Age: 18Years +All GendersPhase 3
75 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of two drugs, inebilizumab and blinatumomab, in adults with active and treatment-resistant autoimmune diseases, including systemic lupus erythematosus SLE with nephritis and rheumatoid arthritis RA. This Phase 2 trial includes several subprotocols to study these medications in different patient groups and disease conditions. Participants may receive inebilizumab through intravenous infusions in either three or four doses, or blinatumomab via subcutaneous injections at low, medium, or high doses. The trial includes parts where doses are determined based on earlier results. The treatments are studied in subgroups of patients with SLE with or without nephritis and in patients with active refractory RA. Throughout the study, participants will be monitored for treatment-emergent adverse events and serious adverse events up to 52 weeks. Various clinical measures for kidney response, disease remission, and disease activity scores will be assessed at multiple time points. Safety, drug levels, antibody formation, and disease activity changes will be tracked regularly, with a total study duration extending up to 52 weeks for outcome evaluations.

Age: 18Years - 75YearsAll GendersPhase 2
58 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.

Age: 55Years - 90YearsAll GendersPhase 3
143 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
P

Actively Recruiting

Researchers are evaluating efimosfermin alfa in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis MASH and stage F2 or F3 liver fibrosis. The study aims to assess the safety and effectiveness of efimosfermin alfa compared to a placebo in resolving steatohepatitis and improving liver-related clinical outcomes. This Phase 3 trial is randomized, double-blind, and placebo-controlled, focusing on participants with specific liver conditions and metabolic syndrome components. Participants are assigned to one of three groups two groups receive different dose levels of efimosfermin alfa, while the third group receives a placebo. Treatments are given under controlled conditions, and the study follows a parallel design. The trial monitors participants at set intervals over a course of 52 weeks, with some outcomes tracked up to 48 months to evaluate long-term effects on liver fibrosis and steatohepatitis. During the study, participants undergo liver biopsies to confirm diagnosis and assess changes. Researchers evaluate improvements in fibrosis stage, steatohepatitis resolution, and various liver function measurements using imaging and blood tests. Safety is monitored by tracking adverse events and laboratory abnormalities. Quality of life and other health indicators are also assessed throughout the study, which lasts several years to capture both short- and long-term outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
91 locations
P

Actively Recruiting

The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.

Age: 18Years - 80YearsAll GendersPhase 3
370 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and effects of updated COVID-19 vaccines called BNT162b2 in people aged 5 to 64 years who have risk factors for severe COVID-19 and in those aged 65 years and older. This Phase 3 study aims to understand how these vaccines work for prevention and to assess their tolerability and immune response. Participants must be medically stable and have no recent COVID-19 infection or vaccination. Participants in Cohort 1 receive a single age-appropriate dose of BNT162b2 vaccine targeting the 20262027 recommended COVID-19 strain, with doses of 30 mcg for those 12 years and older and 10 mcg for children 5 to 11 years old. Cohort 2 participants are randomly assigned to receive one injection of one of three variant-adapted BNT162b2 vaccines. All injections are given in the upper arm and participants and study staff are blinded in Cohort 2. The study lasts about 6 months with at least three visits. Participants track side effects and complete diaries after visits. For Cohort 1, nose swabs and blood samples are taken at two visits, while for Cohort 2 these samples are collected at every visit. Researchers measure local and systemic reactions, adverse events, serious adverse events, and immune responses such as geometric mean fold rise and seroresponse to evaluate vaccine safety and effects over time.

Age: 5Years +All GendersPhase 3
14 locations

1-10 of 45

1